$149 - $199 for 1 month
(15ml for $149 & 30ml for $199)
Semaglutide 0..75mg/ml Suspension for SL Administration
Patent Pending Formula
Easy, once-daily dosing
No shots. No needles. No refrigeration. No supply issues.
Once daily dosing can smooth out drug concentrations.
Taking smaller doses more frequently can reduce the difference between peak medication levels and the lowest levels, leading to a smoother steady state concentration…so shorter spikes the medication levels in your system.
GLP-1 Receptor Agonists
The usage of GLP-1 receptor agonists has grown worldwide. This class includes several different injectable medications, as well as an orally delivered drug. Many patients would prefer to avoid injections if possible, and there is an extremely low absorption of oral tablets (less than 1% per the labeling for RYBELSUS®).
For these reasons, prescribers and patients may prefer a patent-pending compounded formulation of Semaglutide.
20% ??? of an applied sublingual semaglutide suspension dose was shown to pass through oral mucous membrane
What is Sublingual Semaglutide and how is it different?
Sublingual (SL) Semaglutide is a compounded suspension of semaglutide that is designed to be administered under the tongue (sublingually). Our patent-pending formulation utilizes the contents of Rybelsus® tablets and a special base designed with the intent to carry large molecules (high molecular weight substances), such as semaglutide, through the oral mucosal membrane. In an in vitro study, 20% ??? of an applied sublingual semaglutide suspension dose was shown to pass through the oral mucous membrane.
It's all about the base…The specialty base utilized was designed with the intent to improve contact time, permeability, and solubility while maintaining stability, dispersibility, and taste.
What is the dosage and How is it Supplied?
Semaglutide 0.75mg/ml Compounded Suspension
The medication comes in an amber bottle with a 1ml dropper for easy under-the-tongue administration. It should be stored at room temperature and shaken before use. The dose determined by your doctor should be applied under your tongue for a minimum of 1 minute (ideally 5 minutes) and then swallowed. Avoid eating or drinking anything for 30 minutes after administration.
If you are starting semaglutide for the first time, you will be instructed to begin with a titration as directed by your provider. This means that you will start with a smaller dose and increase over time. Titrating this medication can help reduce gastrointestinal side effects and nausea. After each dosage increase it can take up to 4-5 weeks to reach maximum drug concentrations for that dose.
0.25ml once daily x 2 weeks, then
0.5ml once daily x 4 weeks
1ml once daily thereafter (adjusted as needed)
(Providers: Semaglutide has a half life of 7 days and will usually take 4-5 weeks to reach steady state drug concentrations. This is an important consideration when titrating the dose. Also, since the doses are daily instead of weekly, patients can experience shorter spikes from trough to peak drug levels)
Compounded Semaglutide 0.75mg/ml Suspension
$149 for 15ml
$199 for 30ml
How do I get Sublingual Semaglutide?
Sublingual Semaglutide is available with a valid prescription from your healthcare provider. Once we have a prescription we will reach out to you to set up delivery and payment. Prescriptions are $230 for a 1 month supply and shipping is free.
We have created a prescription order form (see below) that you may print and bring to your appointment to discuss this medication with your provider. The second page of this document will provide more information to bring along to your appointment. Your provider can fax the order form to our pharmacy at 732-381-7665. Your prescriber can also prescribe electronically or simply call us at 732-381-7860 EXTENTION 0.
If you are a prescriber with questions please complete our form below OR simply call or text us at 732-381-7860 and one of our knowledgeable staff will communicate with you.
The links below are being worked on and will house a great deal of information related to this patent-pending compounded formulation as well as white papers related to Semaglutide and GLP-1 receptor agonist medications in general.
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist. GLP-1 receptor agonists usage has grown worldwide. This class includes several different injectable medications, as well as an orally delivered drug.
Semaglutide has been used for years to help patients with type 2 diabetes control their blood sugar. It has several different indications for patients with diabetes, in which it is marketed by Novo Nordisk under the brand names Ozempic®, an injectable, and Rybelsus®, an oral tablet. In 2021 the FDA approved another semaglutide containing injectable drug, Wegovy®, to help patients with weight management. These medications have been described by many to suppress one’s appetite and reduce food cravings. A suppressed appetite and reduced food cravings can lead to a decrease in caloric intake.
Although there are specific FDA-approved indications that are available from reviewing the Prescriber Information (“PI”) included in the labeling of the respective medications, you can often look at past or ongoing clinical trials for information about the medication. Please see the Clinical Trials white paper above for more information.
Compounded Sublingual Semaglutide Suspension is a compounded medication, and the FDA does not review compounded medication for safety or efficacy.
What are the Side Effects?
The most common side effects include gastrointestinal related symptoms such as abdominal pain, constipation, diarrhea, nausea, and vomiting. These side effects may be more common after initiation and during dose escalation. Extreme sensitivity reactions such as rash, trouble breathing, swelling of the mouth, face, or throat will require immediate medical attention. Low blood sugar can occur, especially if taking medication for diabetes. If a low blood sugar is suspected, discontinuing the use of the medication may be necessary should these reactions occur.
The FDA does not review any compounded medication from any pharmacy for safety or efficacy. RYBELSUS® is a registered trademark of Novo Nordisk A/S. Formulas and/or material listed are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care, or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.